- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05571189
Heimrehabilitation nach akuter Lungenembolie
The purpose of this study is to evaluate whether a home rehabilitation program after hospitalization for acute pulmonary embolism (PE) improves clinical outcomes at 3 months compared to usual care. Daily physical activity tasks that incorporate heart rate monitoring will be sent through email or text. This information could help improve the management of acute PE.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
New York
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- English speaking (>18 years old). Daily messages will be sent in English.
- Acute PE with right ventricular enlargement or dysfunction defined by echocardiogram report, CT Angiogram report, or elevated cardiac biomarker (NT-pro BNP or troponin).
- Baseline testing started within 7 days of hospital discharge.
Exclusion Criteria:
- Pregnancy.
- Cardiac Effort >2.5 beats/m during 6MWT. This is for safety.
- Cardiac Effort <1.2 beats/m during 6MWT. They are unlikely to benefit.
- Resting tachycardia >120 beats/m during screening or at hospital discharge.
- Suspicion for Chronic Thromboembolic Pulmonary Hypertension.
- Systolic blood pressure >180 mmHg during screening or at hospital discharge.
- Inability to walk.
- Estimated prognosis <12 months at the time of discharge due to underlying co-morbidities.
- Advanced neurologic disease.
- Lack of access to email or text messaging.
- Inability to follow daily instructions.
- Participation in a structured exercise routine at least three days per week in the prior four weeks.
- Principal Investigator discretion
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Participants who receive daily activity message
The intervention group will receive instructions for a daily activity sent through SMS text message or email. |
Participants will receive a text each day with instructions about the daily activity they should complete for that day. |
|
Placebo-Komparator: Participants who receive control message
The control group will receive daily messages to help with blinding sent through text message or email. The messages will not include activity tasks and will include phrases such as "I hope you have a good day". |
Participants will receive a text each day with no instructions about daily activity. It will have messages like "have a nice day." |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
mean change in vector magnitude count as measured by actigraphy
Zeitfenster: 10 weeks
|
The Actigraph triaxial accelerometer will be used to monitor continuous activity at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the vector magnitude count. |
10 weeks
|
|
mean change in mean amplitude deviation as measured by actigraphy
Zeitfenster: 10 weeks
|
The Actigraph triaxial accelerometer will be used to monitor continuous activity at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the mean amplitude deviation. |
10 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
mittlere Änderung in 6 Minuten zu Fuß erreichbar
Zeitfenster: 12 Wochen
|
12 Wochen
|
|
|
mittlere Änderung der Herzfrequenz während eines 6-minütigen Spaziergangs
Zeitfenster: 12 Wochen
|
12 Wochen
|
|
|
Anteil oder Probanden, die eine chronische thromboembolische pulmonale Hypertonie entwickeln
Zeitfenster: 12 Wochen
|
12 Wochen
|
|
|
proportion of participants with post-PE syndrome
Zeitfenster: 12 weeks
|
Participants will be evaluated by a physician to determine if they have post PE-syndrome |
12 weeks
|
|
mean change in steps as measured by Actigraph
Zeitfenster: 12 weeks
|
The Actigraph triaxial accelerometer will be used to monitor the number of steps taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the step count. |
12 weeks
|
|
mean change in activity as measured by Actigraph
Zeitfenster: 12 weeks
|
The Actigraph triaxial accelerometer will be used to monitor the amount of activity taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the amount of activity. |
12 weeks
|
|
mean change in quality of life as measured by PROMIS
Zeitfenster: 12 weeks
|
The PROMIS questionnaire ranges from 0-99 with higher scores indicating worse outcome. |
12 weeks
|
|
mean change in quality of life as measured by Emphasis 10
Zeitfenster: 12 weeks
|
The Emphasis 10 questionnaire ranges from 0-50 with higher scores indicating worse quality of life. |
12 weeks
|
|
mean change in quality of life as measured by Pulmonary Embolism quality of life questionnaire
Zeitfenster: 12 weeks
|
The pulmonary embolism quality of life questionnaire ranges from 1 to 27 with higher scores indicating worse outcomes. |
12 weeks
|
|
mean change in oxygen use during a 6 minute walk
Zeitfenster: 12 weeks
|
Oxygen use will be measured by a measured by portable K5 metabolic analyzer. |
12 weeks
|
|
mean change in carbon dioxide production during a 6 minute walk
Zeitfenster: 12 weeks
|
Carbon Dioxide use will be measured by a measured by portable K5 metabolic analyzer. |
12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Daniel Lachant, DO, University of Rochester
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- STUDY00007680
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .